## Yasuhiro Abe

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5234800/publications.pdf

Version: 2024-02-01

88	3,201	31	55
papers	citations	h-index	g-index
112	112	112	4975
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Approaches to supply bioequivalent oral solid pharmaceutical formulations through the lifecycles of products: Four-media dissolution monitoring program in Japan. Journal of Drug Delivery Science and Technology, 2020, 56, 101378.	1.4	1
2	Relationship Between Geometric and Aerodynamic Particle Size Distributions in the Formulation of Solution and Suspension Metered-Dose Inhalers. AAPS PharmSciTech, 2020, 21, 158.	1.5	3
3	Morphological Analysis of Spherical Adsorptive Carbon Granules Using Three-Dimensional X-Ray Micro-computed Tomography. Chemical and Pharmaceutical Bulletin, 2020, 68, 179-180.	0.6	O
4	Temperature-Dependent Formation of <i>N</i> -Nitrosodimethylamine during the Storage of Ranitidine Reagent Powders and Tablets. Chemical and Pharmaceutical Bulletin, 2020, 68, 1008-1012.	0.6	22
5	Utilization of Diluted Compendial Media as Dissolution Test Solutions with Low Buffer Capacity for the Investigation of Dissolution Rate of Highly Soluble Immediate Release Drug Products. Chemical and Pharmaceutical Bulletin, 2020, 68, 664-670.	0.6	5
6	Effect of Complex Coacervation with Hyaluronic Acid on Protein Transition in a Subcutaneous Injection Site Model System. Chemical and Pharmaceutical Bulletin, 2020, 68, 1109-1112.	0.6	1
7	Rapid and efficient high-performance liquid chromatography analysis of N-nitrosodimethylamine impurity in valsartan drug substance and its products. Scientific Reports, 2019, 9, 11852.	1.6	36
8	Analysis of an Impurity, <i>N</i> -Nitrosodimethylamine, in Valsartan Drug Substances and Associated Products Using GC-MS. Biological and Pharmaceutical Bulletin, 2019, 42, 547-551.	0.6	17
9	Recombinant immunotoxins targeting B-cell maturation antigen are cytotoxic to myeloma cell lines and myeloma cells from patients. Leukemia, 2018, 32, 569-572.	3.3	9
10	Observation of liposomes of differing lipid composition in aqueous medium by means of atomic force microscopy. Microscopy (Oxford, England), 2016, 65, 383-389.	0.7	16
11	Atomic Force Microscopic Analysis of the Effect of Lipid Composition on Liposome Membrane Rigidity. Langmuir, 2016, 32, 6074-6082.	1.6	100
12	Creation of mouse TNFR2-selective agonistic TNF mutants using a phage display technique. Biochemistry and Biophysics Reports, 2016, 7, 309-315.	0.7	7
13	Cell Type-Specific Responses of Peripheral Blood CD14-Positive Monocytes to Liposome-Encapsulated Immunostimulatory siRNA. Biological and Pharmaceutical Bulletin, 2016, 39, 1859-1867.	0.6	1
14	Identification and evaluation of metastasis-related proteins, oxysterol binding protein-like 5 and calumenin, in lung tumors. International Journal of Oncology, 2015, 47, 195-205.	1.4	50
15	Aminopeptidase P3 (APP3), a novel member of the TNF/TNFR2 signaling complex, induces phosphorylation of JNK. Journal of Cell Science, 2015, 128, 656-69.	1.2	18
16	Intestinal absorption and biological effects of orally administered amorphous silica particles. Nanoscale Research Letters, 2014, 9, 532.	3.1	49
17	Ephrin receptor A10 is a promising drug target potentially useful for breast cancers including triple negative breast cancers. Journal of Controlled Release, 2014, 189, 72-79.	4.8	44
18	788: Expression of Annexin A4 regulates cisplatin-susceptibility in malignant mesothelioma. European Journal of Cancer, 2014, 50, S190.	1.3	0

#	Article	IF	Citations
19	Eph receptor A10 has a potential as a target for a prostate cancer therapy. Biochemical and Biophysical Research Communications, 2014, 450, 545-549.	1.0	27
20	Intranasal exposure to amorphous nanosilica particles could activate intrinsic coagulation cascade and platelets in mice. Particle and Fibre Toxicology, 2013, 10, 41.	2.8	61
21	A targeted adenovirus vector displaying a human fibronectin type III domain-based monobody in a fiber protein. Biomaterials, 2013, 34, 4191-4201.	5.7	10
22	Liver-specific microRNAs as biomarkers of nanomaterial-induced liver damage. Nanotechnology, 2013, 24, 405102.	1.3	49
23	Expression of Eph receptor A10 is correlated with lymph node metastasis and stage progression in breast cancer patients. Cancer Medicine, 2013, 2, 972-977.	1.3	34
24	Abstract C119: Anti-EphA10 monoclonal antibody is a potential therapy against EphA10 positive breast cancer, 2013,,.		1
25	Amorphous nanosilicas induce consumptive coagulopathy after systemic exposure. Nanotechnology, 2012, 23, 045101.	1.3	62
26	986 Detection of Drug-target Proteins on Tumor-derived Exosomes by ELISA Using Anti-CD81 Antibodies. European Journal of Cancer, 2012, 48, S238.	1.3	0
27	Distribution and histologic effects of intravenously administered amorphous nanosilica particles in the testes of mice. Biochemical and Biophysical Research Communications, 2012, 420, 297-301.	1.0	68
28	Annexin A4 is a possible biomarker for cisplatin susceptibility of malignant mesothelioma cells. Biochemical and Biophysical Research Communications, 2012, 421, 140-144.	1.0	25
29	Hemopexin as biomarkers for analyzing the biological responses associated with exposure to silica nanoparticles. Nanoscale Research Letters, 2012, 7, 555.	3.1	15
30	Amorphous silica nanoparticles enhance cross-presentation in murine dendritic cells. Biochemical and Biophysical Research Communications, 2012, 427, 553-556.	1.0	40
31	Surface modification of amorphous nanosilica particles suppresses nanosilica-induced cytotoxicity, ROS generation, and DNA damage in various mammalian cells. Biochemical and Biophysical Research Communications, 2012, 427, 748-752.	1.0	51
32	Amorphous silica nanoparticles size-dependently aggravate atopic dermatitis-like skin lesions following an intradermal injection. Particle and Fibre Toxicology, 2012, 9, 3.	2.8	75
33	Potential of acute-phase proteins as biomarkers for sub-nano platinum exposure. Die Pharmazie, 2012, 67, 958-9.	0.3	3
34	9068 POSTER The Relationship Between Oxysterol Binding Protein Like 5 and Calumenin During Lymph Node Metastasis. European Journal of Cancer, 2011, 47, S612.	1.3	0
35	PS2-054 Biological and structural characterization of human TNFR2-selective TNF mutants. Cytokine, 2011, 56, 78.	1.4	0
36	Limited expression of reticulocalbin-1 in lymphatic endothelial cells in lung tumor but not in normal lung. Biochemical and Biophysical Research Communications, 2011, 405, 610-614.	1.0	8

#	Article	IF	CITATIONS
37	Silica and titanium dioxide nanoparticles cause pregnancy complications in mice. Nature Nanotechnology, 2011, 6, 321-328.	15.6	622
38	Therapeutic effect of PEGylated TNFR1-selective antagonistic mutant TNF in experimental autoimmune encephalomyelitis mice. Journal of Controlled Release, 2011, 149, 8-14.	4.8	49
39	Effect of amorphous silica nanoparticles on in vitro RANKL-induced osteoclast differentiation in murine macrophages. Nanoscale Research Letters, 2011, 6, 464.	3.1	19
40	Acute phase proteins as biomarkers for predicting the exposure and toxicity of nanomaterials. Biomaterials, 2011, 32, 3-9.	5.7	54
41	Development of an antibody proteomics system using a phage antibody library for efficient screening of biomarker proteins. Biomaterials, 2011, 32, 162-169.	5.7	31
42	Promotion of allergic immune responses by intranasally-administrated nanosilica particles in mice. Nanoscale Research Letters, 2011, 6, 195.	3.1	50
43	Effect of surface properties of silica nanoparticles on their cytotoxicity and cellular distribution in murine macrophages. Nanoscale Research Letters, 2011, 6, 93.	3.1	71
44	Amorphous nanosilica induce endocytosis-dependent ROS generation and DNA damage in human keratinocytes. Particle and Fibre Toxicology, 2011, 8, 1.	2.8	229
45	Systemic distribution, nuclear entry and cytotoxicity of amorphous nanosilica following topical application. Biomaterials, 2011, 32, 2713-2724.	5.7	161
46	Fine tuning of receptor-selectivity for tumor necrosis factor-α using a phage display system with one-step competitive panning. Biomaterials, 2011, 32, 5498-5504.	5.7	15
47	Identification of New Candidates as Mucosal Vaccine Adjuvant in TNF Family Cytokines. Advances in Experimental Medicine and Biology, 2011, 691, 299-304.	0.8	1
48	Anti-inflammatory Effects of a Novel TNFR1-Selective Antagonistic TNF Mutant on Established Murine Collagen-Induced Arthritis. Advances in Experimental Medicine and Biology, 2011, 691, 493-500.	0.8	5
49	Size-dependent immune-modulating effect of amorphous nanosilica particles. Die Pharmazie, 2011, 66, 727-8.	0.3	10
50	Urban Aerosols Induce Pro-inflammatory Cytokine Production in Macrophages and Cause Airway Inflammation in Vivo. Biological and Pharmaceutical Bulletin, 2010, 33, 780-783.	0.6	14
51	Interleukin-1 Family Cytokines as Mucosal Vaccine Adjuvants for Induction of Protective Immunity against Influenza Virus. Journal of Virology, 2010, 84, 12703-12712.	1.5	109
52	Carbon Nanotubes Elicit DNA Damage and Inflammatory Response Relative to Their Size and Shape. Inflammation, 2010, 33, 276-280.	1.7	143
53	202 Identification and evaluation of novel breast cancer related biomarker proteins by antibody proteomics technology. European Journal of Cancer, Supplement, 2010, 8, 53.	2.2	0
54	Generation of mouse macrophages expressing membrane-bound TNF variants with selectivity for TNFR1 or TNFR2. Cytokine, 2010, 50, 75-83.	1.4	5

#	Article	IF	CITATIONS
55	SS5-5 Anti-inflammatory effects of a novel TNFR1-selective antagonistic TNF mutant in murine experimental autoimmune encephalomyelitis. Cytokine, 2010, 52, 45.	1.4	O
56	Potential adjuvant effect of intranasal urban aerosols in mice through induction of dendritic cell maturation. Toxicology Letters, 2010, 199, 383-388.	0.4	10
57	Size-dependent cytotoxic effects of amorphous silica nanoparticles on Langerhans cells. Die Pharmazie, 2010, 65, 199-201.	0.3	62
58	The use of a mutant TNF- $\hat{l}_{\pm}$ as a vaccine adjuvant for the induction of mucosal immune responses. Biomaterials, 2009, 30, 5869-5876.	5.7	33
59	The augmentation of intracellular delivery of peptide therapeutics by artificial protein transduction domains. Biomaterials, 2009, 30, 3318-3323.	5.7	9
60	The treatment of established murine collagen-induced arthritis with a TNFR1-selective antagonistic mutant TNF. Biomaterials, 2009, 30, 6638-6647.	5.7	50
61	Frequent expression of TRAIL-R2 in human breast tumors revealed by antibody proteomics technology. Cytokine, 2009, 48, 54-55.	1.4	0
62	Creation of a mutant IFN- $\hat{l}\pm 8$ with enhanced anti-HCV activity using the phage display technique. Cytokine, 2009, 48, 58.	1.4	0
63	Characterization of mucosal and systemic immune responses elicited by interleukin cytokines as mucosal adjuvant against influenza virus. Cytokine, 2009, 48, 109.	1.4	0
64	TNF superfamily member, TL1A, is a potential mucosal vaccine adjuvant. Biochemical and Biophysical Research Communications, 2009, 384, 296-300.	1.0	16
65	Novel protein engineering strategy for creating highly receptor-selective mutant TNFs. Biochemical and Biophysical Research Communications, 2009, 388, 667-671.	1.0	7
66	Structureâ€"Function Relationship of Tumor Necrosis Factor (TNF) and Its Receptor Interaction Based on 3D Structural Analysis of a Fully Active TNFR1-Selective TNF Mutant. Journal of Molecular Biology, 2009, 385, 1221-1229.	2.0	65
67	Evaluation of size-dependent acute toxicity and toxicokinetics of amorphous nanosilicas. Toxicology Letters, 2009, 189, S181-S182.	0.4	1
68	Evaluation of size-dependent intracellular distribution and genotoxicity of amorphous nanosilicas in human keratinocytes. Toxicology Letters, 2009, 189, S183.	0.4	0
69	Urban aerosol directly stimulates antigen presentation cells in vitro and cause airway inflammation in vivo. Toxicology Letters, 2009, 189, S176-S177.	0.4	0
70	Fast Binding Kinetics and Conserved 3D Structure Underlie the Antagonistic Activity of Mutant TNF: Useful Information for Designing Artificial Proteo-Antagonists. Journal of Biochemistry, 2009, 146, 167-172.	0.9	15
71	Arsenic Trioxide Inhibits Human T Cell-Lymphotropic Virus-1-Induced Syncytiums by Down-Regulating gp46. Biological and Pharmaceutical Bulletin, 2009, 32, 1286-1288.	0.6	2
72	Simple and highly sensitive assay system for TNFR2-mediated soluble- and transmembrane-TNF activity. Journal of Immunological Methods, 2008, 335, 71-78.	0.6	11

#	Article	IF	CITATIONS
73	Organelle-Targeted Delivery of Biological Macromolecules Using the Protein Transduction Domain: Potential Applications for Peptide Aptamer Delivery into the Nucleus. Journal of Molecular Biology, 2008, 380, 777-782.	2.0	24
74	The therapeutic effect of TNFR1-selective antagonistic mutant TNF- $\hat{l}_{\pm}$ in murine hepatitis models. Cytokine, 2008, 44, 229-233.	1.4	47
75	164 Relationship between regulatory T-cell infiltration and progression of different tumors assessed by high-density tissue microarray. Cytokine, 2008, 43, 274.	1.4	O
76	277 Mutant TNF elicits Th2-type responses for enhanced mucosal immunity. Cytokine, 2008, 43, 309.	1.4	0
77	Creation and X-ray Structure Analysis of the Tumor Necrosis Factor Receptor-1-selective Mutant of a Tumor Necrosis Factor-α Antagonist. Journal of Biological Chemistry, 2008, 283, 998-1007.	1.6	89
78	Creation of Novel Cell-Penetrating Peptides for Intracellular Drug Delivery Using Systematic Phage Display Technology Originated from Tat Transduction Domain. Biological and Pharmaceutical Bulletin, 2007, 30, 218-223.	0.6	32
79	102 Creation of TNF Receptor1-Selective Mutant TNF Using Phage Display System. Cytokine, 2007, 39, 28.	1.4	O
80	170 Site-specific PEGylation of a Lysine-deficient TNF Superfamily with Full Bioactivity. Cytokine, 2007, 39, 47.	1.4	0
81	Role of amino acid residue 90 in bioactivity and receptor binding capacity of tumor necrosis factor mutants. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2007, 1774, 1029-1035.	1.1	7
82	A novel method for construction of gene fragment library to searching epitopes. Biochemical and Biophysical Research Communications, 2006, 346, 198-204.	1.0	6
83	Quality Enhancement of the Non-immune Phage scFv Library to Isolate Effective Antibodies. Biological and Pharmaceutical Bulletin, 2006, 29, 1325-1330.	0.6	25
84	Creation of Novel Protein Transduction Domain (PTD) Mutants by a Phage Display-Based High-Throughput Screening System. Biological and Pharmaceutical Bulletin, 2006, 29, 1570-1574.	0.6	25
85	Promotion of Optimized Protein Therapy by Bioconjugation as a Polymeric DDS. Anti-Cancer Agents in Medicinal Chemistry, 2006, 6, 251-258.	0.9	8
86	Functionalization of Tumor Necrosis Factor- $\hat{l}_{\pm}$ Using Phage Display Technique and PEGylation Improves Its Antitumor Therapeutic Window. Clinical Cancer Research, 2004, 10, 8293-8300.	3.2	76
87	Optimal site-specific PEGylation of mutant TNF- $\hat{l}\pm$ improves its antitumor potency. Biochemical and Biophysical Research Communications, 2004, 315, 808-814.	1.0	50
88	Selective Enhancer of Tumor Vascular Permeability for Optimization of Cancer Chemotherapy. Biological and Pharmaceutical Bulletin, 2004, 27, 437-439.	0.6	5